MedTrace Logo

Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults

NCT06794255 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-06-27

No results posted yet for this study

Summary

The purpose of this clinical trial is to understand whether oral vitamin C can help delay the aging of middle-aged and elderly individuals, search for sensitive biomarkers of human aging, and provide new paradigms and scientific guidance for aging intervention with small molecule drugs. The main questions it aims to answer are as follows:

* Can oral vitamin C effectively improve the aging-related indicators?
* What is the safety of participants when taking vitamin C supplements?

Researchers will compare vitamin C with a placebo to observe whether vitamin C is effective in intervening in the aging of middle-aged and elderly individuals. Participants need to:

* Take 2 tablets (250mg/tablet) of vitamin C or placebo after breakfast and dinner every day for 12 consecutive months;
* Go to the designated place for a face-to-face follow-up every 6 months and receive a telephone follow-up every 2 months, and pick up subsequent drugs during the follow-up;
* Honestly inform the medication situation during each follow-up;
* Report any discomfort or adverse reactions that occur during the treatment process to the researchers;
* Fill in a questionnaire about their own health status during each follow-up;
* After 6 months and 12 months of intervention, conduct a comprehensive health examination as required, including blood tests and other items.

Conditions

  • Ageing

Interventions

DIETARY_SUPPLEMENT

Vitamin C

Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.

OTHER

Placebo

Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.

Sponsors & Collaborators

  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER

  • People's Hospital of Quzhou

    collaborator OTHER

  • Peking University Third Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-02
Primary Completion
2026-01-30
Completion
2027-01-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06794255 on ClinicalTrials.gov